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This study is a prospective randomized double-blind controlled trial whose aim was to investigate the clinical eﬀects of aromatic
essential oils in patients with upper respiratory tract infections. The trial was conducted in six primary care clinics in northern
Israel. A spray containing aromatic essential oils of ﬁve plants (Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita,
Origanum syriacum, and Rosmarinus oﬃcinalis)as applied 5 times a day for 3 days and compared with a placebo spray. The main
outcome measure was patient assessment of the change in severity of the most debilitating symptom (sore throat, hoarseness or
cough). Sixty patients participated in the study (26 in the study group and 34 in the control group). Intention-to-treat analysis
showed that 20 minutes following the spray use, participants in the study group reported a greater improvement in symptom
severity compared to participants in the placebo group (P = .019). There was no diﬀerence in symptom severity between the two
groups after 3 days of treatment (P = .042). In conclusion, spray application of ﬁve aromatic plants reported in this study brings
about signiﬁcant and immediate improvement in symptoms of upper respiratory ailment. This eﬀe c ti sn o ts i g n i ﬁ c a n ta f t e r3d a y s
of treatment.
1.Introduction
Herbal medicine is one of the main modalities in traditional
as well as complementary and alternative medicine (CAM)
and is increasingly acknowledged due to the extensive use
of herbal remedies amongst the general population in
developed and developing countries worldwide [1, 2]. The
use of herbs for treatment of respiratory ailments has been
common in the Middle East for thousands of years [3].
During the last three decades, several ethnobotanical surveys
wereconductedin Israeland the Palestinian Authority which
elucidated the use of 25 diﬀerent herbs for the treatment of
respiratory conditions [4, 5].
In vitro and clinical studies suggest the therapeutic
potential of aromatic herbs in treatment of respiratory ail-
ments. Aromatic herbs possess broad-spectrum pharmaco-
logical properties and are used as traditional remedies as well
as culinary herbs. Mentha piperita (peppermint) contains
menthol and exhibits antibacterial and antiviral properties
[6]a sw e l la sa na n t i t u s s i v ee ﬀect (in a study of guinea pigs)
[7]. Origanum syriacum contains the active ingredients of
thymol and carvacrol and possesses antimicrobial [8]a n d2 Evidence-Based Complementary and Alternative Medicine
antifungal [9] properties. Boskabady and Jandaghi studied
carvacrol in guinea pigs and found a bronchodilator eﬀect
[10]. A relaxant eﬀect on tracheal smooth muscle was also
demonstrated in rabbits and guinea pigs exposed to volatile
oil of Rosmarinus oﬃcinalis (which contains camphor and
cineol) [11]. Lu et al. found that Eucalyptus globulus oil
(of which cineole is the major active ingredient) has an
anti-inﬂammatory eﬀect on chronic bronchitis induced by
lipopolysaccharide in rats and inhibits the hypersecretion
of airway mucins [12]. Kaspar et al. studied secretolytic
changes of ciliary frequency and lung function in patients
with obstructive lung disease and found beneﬁcial eﬀects of
cineol [13]. Silva et al. found that both Eucalyptus globulus
and Eucalyptus citriodora (containing citronellal) have cen-
tral and peripheral analgesic eﬀects as well as neutrophil-
dependent and neutrophil-independent anti-inﬂammatory
properties[14].CohenandDresslerconductedaclinicaltrial
with patients suﬀering from acute runny nose who reported
improved breathing following treatment with a volatile oil
mixture of eucalyptus, menthol, and camphor [15]. In
Germany, Kehrl et al. conducted a randomized controlled
double-blind study in patients with acute nonpurulent
rhinosinusitis and found that timely treatment with cineole
is eﬀective in reducing rhinosinusitis symptoms and is safe
before antibiotics are indicated [16].
The limited evidence-based conventional treatment con-
cerning upper respiratory tract infections (URTIs) [17]l e d
the authors to study the potential of aromatic plants in
alleviating URTI symptoms. Based on the evidence in the
medical literature and knowledge of traditional medicine,
the authors designed a prospective trial of aromatic plants
growing in Israel that are often used by complementary
medicine practitioners in Israel for the treatment of URTIs.
2. Methods
2.1. Study Sites and Participants. A total of 60 adult volun-
teers aged from 21 to 66 years were recruited to participate
in this study. Participants were eligible if they were older
than 18 years, had URTI symptoms and a clinical diagnosis
of pharyngotonsillitis, viral laryngitis, or viral tracheitis, and
gave informed consent.
Patients were excluded for a diagnosis of acute follicu-
lar tonsillitis, peritonsillar abscess, asthma, current use of
antibiotic treatment, Coumadin, immunosuppressive drugs,
known hypersensitivity to aromatic essential oils, and preg-
nancy. Primary care physicians oﬀered eligible patients to
participate in the study in six family medicine clinics in
Northern Israel, operated by Clalit Health Services, the
largest health maintenance organization in Israel.
The study was administered after completing a review
processandobtainingapprovalbytheHelsinkiReviewBoard
of Ha’Emek Medical Center, Afula, Israel and registered
at http://www.clinicaltrials.gov/ (NCT00611390). The study
was performed at six primary care clinics during the winter
of 2007-2008.
2.2. Study Design. This study was a double-blind random-
ized controlled trial of a spray containing aromatic essential
oils of ﬁve herbs (Eucalyptus citriodora, Eucalyptus globulus,
Mentha piperita, Origanum syriacum, and Rosmarinus oﬃci-
nalis) compared with a placebo spray.
Figure 1 illustrates the study methodology using a three-
step evaluation. After signing an informed consent form,
patients were asked to participate in a baseline evaluation
thatincludedthephysician’sclinicalassessment,athroatcul-
ture, and a record of demographics. In addition, participants
were asked to assess the severity of 6 symptoms on a 4-
degree scale (0: no symptoms, 1: mild, 2: moderate, and 3:
severe). The symptoms assessed by the patients included the
following: fatigue, sore throat, cough, hoarseness or loss of
voice, pain when talking, and diﬃculty in breathing. Severity
of the ailment (henceforth clinical score) was based on a
score combining these 6 symptoms assessed by patients and
4 signs assessed by the physician (stridor, dyspnea, mucous
secretion, and systemic fever >38◦C). Each sign was graded
as 0 (none) or 1 (positive sign). Thus, the highest severity
of the clinical score of the 6 symptoms (highest score 3) and
4 signs (highest score 1) was 22. Patients were categorized
as having a more severe disease if their initial clinical score
was higher than 8. In order to avoid inclusion of patients
with rhino-sinusitis, the severity of another 4 symptoms was
assessed (including runny nose, nasal obstruction, facial and
forehead pain, and diﬃculty when swallowing).
Following the baseline evaluation, participants were
randomized to use either a herbal or placebo spray. The
sprays were packaged in identical bottles in a box containing
5 herbal and 5 placebo bottles arranged randomly. Study
investigators and participants were blinded to study groups
and data until the trial was completed. Participants were
asked to use the spray with the indicator pointed to their
throat by applying 4 sprayings each time every 5 minutes,
outside the physician’s room. After 20 minutes, the partic-
ipants were evaluated for 3 major symptoms (sore throat,
hoarseness, and cough) and general appraisal of the spray
taste, smell, and other sensations. Following this evaluation,
participants were advised to apply the spray at home for
consecutive 3 days in a dosage of 4 sprayings each time,
5 times a day. Following 3 days of treatment, participants
were invited for a ﬁnal evaluation at their physician’s oﬃce
that included assessment of use (compliance assessment:
dosagethatwasactuallyusedbyevaluationofemptybottles),
general appraisal of the spray characteristics (e.g., sensations
causedbythespray),patient’sevaluationofthesprayeﬃcacy,
and speciﬁc evaluation of the symptoms using the same
4-degree scale. Physicians assessed the participants’ clinical
status and recorded throat culture results.
2.3. Aromatic Herbal Remedy Preparation. The aromatic
herbal remedy was prepared in the Department of Aromatic,
Medicinal and Spice Crops at the Newe Ya’ar Research
Center of the Agricultural Research Organization in Israel.
The fresh plant materials were hydrodistilled for 1.5 hours
in a modiﬁed Clevenger apparatus. The essential oil was
cooled and separated from the accompanying water. Samples
consisting of 1mL diluted essential oils (1:10,000 in hexane)
were analyzed on a GC-MSD apparatus (6890N, Agilent),
with quadrupole detectors and electron ionization in 70Ev,Evidence-Based Complementary and Alternative Medicine 3
90 individuals screened for eligibility
60 eligible participants
assigned randomly to groups
24 excluded for not meeting criteria
4 did not consent to participate
2 excluded due to low symptom severity
26 assigned to the study group 34 assigned to the control group
1st baseline assessment
2nd assessment:
20 minutes following treatment
3rd assessment:
3 days following treatment
32 protocol completers 25 protocol completers
34 included in intention-to-treat analysis
1 failed to show up for any
postbaseline visits
26 included in intention-to-treat analysis
2 failed to show up for any
postbaseline visits
Figure 1: Trial proﬁle: disposition of screened, randomized, and analyzed patients.
Rosmarinus oﬃcinalis
Eucalyptus globulus
Eucalyptus citriodora
Mentha piperita
Origanum syriacum
Spray containing aromatic
essential oils of ﬁve plants
No diﬀerence in symptom severity
between the two groups
Hypothesis:
Local anti-inﬂammatory
and analgesic eﬀect
Hypothesis:
Natural improvement
self limiting disease
F o l l o w i n g3d a y s
Following 20 minutes
Compared to placebo
signiﬁcant improvement
in cough, sore throat or hoarseness
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equipped with a 30m × 0.25mm fusedsilica capillary col-
umn (Rtx-5SIL MS, Restek). Helium was used as the carrier
gas at a constant pressure of 49 psi. Injector temperature was
250◦C, and transfer line temperature was 280◦C. Run condi-
tions were 50◦C for 1min, followed by temperature increase
from 50◦ to 260◦Ca tar a t eo f5 ◦C/min, and 6min holding.
Samples were injected in split mode. Data were collected
withinamassrangeof41–350m/z.Identiﬁcationofthemain
components was done by coinjection of authentic standards,
and comparison of the electron ionization mass spectra was
obtained from authentic standards and complemented with
computerized libraries.
The aromatic herbal remedy was a mixture of aromatic
oils of 5 herbs: 20% Mentha piperita, 10% Eucalyptus citri-
odora, 20% Eucalyptus globulus, 20% Rosmarinus oﬃcinalis,
and 30% Origanum syriacum. The oil mixture was added
to 97% solvent of Polysorbate 80. The ﬁnal mixture was
packed in 20mL packages with a spray device. Every pressing
produced ﬁne solution drops of 0.1mL consisting of 3mcg
of the aromatic oil mixture. Thus, patients receiving the
aromatic spray were given, on the ﬁrst day of the trial, a
dosage of 48mcg of the aromatic oil mixture (4 cycles of 4
sprayingseachtime,every5minutes).Duringthenext3days
participants used a daily dosage of 60mcg of the aromatic
mixture (4 sprayings each time, 5 times a day).
The placebo solution is constituted of water, Polysorbate
80, and authorized Lemon VIP additive (produced by
Florasynth Co.) at a concentration of 0.1%. The placebo
solution was packed identically to the herbal solution. The
researchers assessed the placebo solution and found its taste
and smell comparable to the aromatic solution although
not identical. Patients’ assessment of taste and smell are
presented in Section 3.
2.4. Statistical Analysis. Data were evaluated using the SPSS
software program (version 16; SPSS Inc., Chicago, IL). The
trial was designed to produce at least a 50% reduction in
symptom severity between the aromatic herbal spray and
control groups with Power of 80% and 95% conﬁdence
interval. The reduction was in one score on a 4-degree scale
assessing three URTI symptoms (sore throat, hoarseness, or
cough) comparing the aromatic herbal spray group and the
control group following a 20-minute application and a 3-
day followup. Pearson’s chi-square test and Fisher’s exact test
were used to detect diﬀerences in the prevalence of categori-
cal variables and demographic data between the participants
in the two groups (herbal versus placebo spray users). The
primary outcome of the study was a change in one or more
of3URTIsymptoms(sorethroat,hoarseness,andcough)on
a 4-score degree scale. The primary comparison was between
the changes from baseline to 20 minutes in the herbal spray
group compared with the control group using the chi-square
tests. Paired tests, McNemar and t-tests, were calculated to
check diﬀerences in the improvement level after 20 minutes
compared to the 3-day followup in each group. P values
less than .05 were regarded as signiﬁcant. The intention-to-
treatanalysisincludedallparticipantsforwhompostbaseline
valueswereavailable.Insecondaryanalyses,themeanchange
in the 3-URTI symptom scores from baseline to 3 days
was also compared between the herbal spray group and the
control group.
3. Results
3.1. Characteristics of Subjects. The trial proﬁle and selection
of participants are summarized in Figure 1. Among the 90
adults screened for upper respiratory tract infection, 66 met
inclusioncriteria.Sixty-twopatientsconsentedtoparticipate
in the study and completed baseline evaluation. Reasons
for patients’ refusal to participate in the study were as
follows: use of other drugs or supplements for the URTI
symptoms, safety concerns regarding an unproven medi-
cation, and willingness to purchase out-of-study “natural”
medications with no need for doctor’s supervision. Two
patients consented to participate in the baseline assessment
but were excluded due to low scores of symptom severity.
Therefore, 60 participants were ﬁnally enrolled in the study
(26 in the herbal group and 34 in the control group).
Three of the 60 participants completed the evaluations at
baseline and 20 minutes after applying the spray but did
not use the spray for the next 3 days as instructed by the
study protocol. 57 of the 60 participants used the spray as
instructed (compliance rate: 95%). Nevertheless, intention-
to-treat analysis was performed for all 60 participants.
The two study groups had comparable demographic and
clinical characteristics including age, gender, urban/rural
residence, days of illness prior to inclusion, fever, recurrent
tonsillitis background, and severity of debilitating symptoms
(Table 1). In the control group, more participants reported
current smoking (29% versus 8%), but this diﬀerence was
not signiﬁcant (P = .052). Throat cultures were positive
for two patients from the group receiving the herbal spray
and one patient in the placebo group (all of them eventually
received antibiotic treatment).
3.2. Clinical Outcomes. In the intention-to-treat analysis,
there was a signiﬁcant diﬀerence between the clinical scores
ofthetreatmentandcontrolgroups20minutesfollowingthe
spray use (Table 2). Participants in the study group reported
more improvement in the severity of their most debilitating
URTI symptoms compared to participants in the placebo
group (P = .019). Improvement was deﬁned as reduction
of at least one score in symptoms of sore throat, hoarseness,
or cough. Analysis of a sub-population of 46 patients with
the more severe clinical score (the clinical score is described
in Section 2 and combines 6 symptoms and 4 signs) also
showed a signiﬁcant diﬀerence between the treatment and
placebo groups (P = .009).
Therewasnodiﬀerenceinsymptomseveritybetweenthe
two groups after 3 days of treatment (P = .42) (Table 2).
Adverse eﬀects due to therapy in both groups were simi-
lar and mild in nature, such as a dry pharynx and/or a slight
stinging sensation. Assessment of blinding was based on the
participants’ report of the spray taste, smell, and burning
and dry sensation following application. Participants in both
groups graded overall spray eﬃcacy similarly. Intermediate
to good eﬃcacy was reported by 16/26 participants (61.5%)
in the aromatic spray group and by 18/33 (54.5%) inEvidence-Based Complementary and Alternative Medicine 5
Table 1: Demographic characteristics of the randomized patient population (n = 60).
Overall (n = 60) Herbal group (n = 26) Control group (n = 34) P value
Age, years, mean (SD) 43.9 ±12.44 6 .6 ±11.94 1 .9 ±12.60 . 1 9 a
Sex (%)
Female 32 (53%) 13 (50%) 19 (56%) 0.79b
Male 28 (47%) 13 (50%) 15 (44%)
Residence, n
Urban 42 (70%) 19 (73%) 23 (68%) 0.78b
Rural 18 (30%) 7 (27%) 11 (32%)
Days of illness prior to inclusion, n
One day 10 (17%) 4 (15%) 6 (17%) 0.96b
Two days 22 (37%) 10 (39%) 12 (35%)
More than two days 28 (47%) 12 (46%) 16 (47%)
Fever >37.5◦C prior to inclusion, %
Yes 14 (23%) 6 (23%) 8 (24%) 1.00b
No 46 (77%) 20 (77%) 26 (76%)
Recurrent tonsillitis, %
Yes 4 (7%) 3 (12%) 1 (3%) 0.31b
No 56 (93%) 23 (88%) 33 (97%)
Current smoker, %
Yes 12 (20%) 2 (8%) 10 (29%) 0.052b
No 48 (80%) 24 (92%) 24 (71%)
Baseline assessment of the most debilitating symptomc
Cough/Hoarseness mean (SD)
Score 1 7 (12%) 3 (11%) 4 (12%) 0.35b
Score 2 29 (48%) 10 (39%) 19 (56%)
Score 3 24 (40%) 13 (50%) 11 (32%)
at-test bFisher’s exact test cThe most severe of the following symptoms: sore throat, hoarseness, or cough.
Table 2: Changes in clinical scores of the most debilitating symptoms from baseline to 20 minutes following spray application and 3-day
followup.
Overall (n = 60) Herbal group
(n = 26)
Control group
(n = 35)
P value
Clinical improvement∗ in the most debilitating
symptom 20 minutes following application, n (%) 33 (55.0) 19 (73.1) 14 (41.2) .019
Clinical improvement∗ in the most debilitating
symptom following 3 day application, n (%) 38 (63.3) 18 (72.0) 20 (58.8) .42
∗Improvementwasdeﬁnedasatleastone-scorereductionina4-degreesymptomscalerangingfrom0to3ofthemostdebilitatingofthefollowingsymptoms:
sore throat, hoarseness, or cough.
the placebo group. Compared to the placebo group, fewer
participants in the aromatic group attributed moderate to
good taste to the spray (9/25 (36%) versus 8/17 (47%)) but
reported a better smell (19/25 (76%) versus 7/18 (38.8%)).
Assessment of compliance was based on the partici-
pants’ reports. Participants in both groups reported taking
maximal dose of spray in the ﬁrst day of treatment (26/26
participants in the aromatic spray group versus 33/34 in the
placebo group). In day 3 of treatment, 25/26 participants
in the aromatic group reported compliance with spray use
(18 reported maximal recommended dosage and 7 partial
dosage)comparedto32participantsinthecontrolgroup(25
reported maximal dosage and 7 partial dosage).
4. Discussion
In this randomized double-blind trial, the eﬀect of a herbal
preparation on URTI symptoms was studied compared to
placebo. Patients reported a signiﬁcant decrease in URTI
symptoms 20 minutes postadministration (P = .019). Anal-
ysis of a sub-population of patients with severe symptoms
(46 participants) showed an even more signiﬁcant diﬀerence
between the treatment and placebo groups (P = .009).
As can be expected in upper respiratory tract infections,
participants in both groups signiﬁcantly improved after 3
days. No statistical diﬀerence was detected between the
herbal and placebo groups after 3 days. These ﬁndings6 Evidence-Based Complementary and Alternative Medicine
suggest that the studied herbal preparation possesses a local,
rather than systemic, eﬀect on the upper respiratory tract.
Following 3 days of treatment, this beneﬁcial eﬀect was
minimized, possibly due to natural improvement of patients’
symptoms that typically characterize URTI (Figure 2).
The trial was conducted in community family medicine
clinics and, therefore, reﬂects URTI management in primary
careratherthanthemoresymptomaticallyseverepopulation
referred to ENT clinics and hospital departments.
This study has several limitations. The small sample
size may limit the interpretation of the study results;
hence, further research is warranted with a larger number
of participants. In addition, although participants in the
two groups had comparable characteristics, smoking in the
controlgroupwasmoreprevalentandnearlysigniﬁcant(P =
.052), thus possible inﬂuence of smoking on participants’
taste and smell cannot be excluded. Another limitation is the
use of only three points of clinical evaluation. Continuous
measures of symptoms (e.g., patient’s symptom diary) may
contribute to learning about the clinical eﬃcacy of the plant
spray along the three days of evaluation. Another limitation
is concerned with the theme of herbal safety. Although we
did not observe any severe side eﬀect symptoms, larger-
scale studies are warranted in order to conclude the safety
of the aromatic herbal formula. An additional limitation
of our study relates to the challenging issue of blinding
in herbal studies, especially when dealing with aromatic
herbs. Although we did not assess participants’ blindness, we
did receive the participants’ assessment regarding the smell
and taste and their overall opinion regarding the spray’s
eﬃcacy. Interestingly, participants receiving the aromatic
spray reported a better smell compared to the placebo group,
but fewer participants reported a good taste. In view of the
fact that the aroma of aromatic herbs includes both smell
and taste, we cannot conclude that blinding in our study
was disrupted. Nevertheless, we recommend direct assess-
ment of blinding in further clinical studies using aromatic
herbs.
Inordertoclarifyourﬁndings,wereviewedtheliterature
and found three randomized controlled studies that studied
remedies containing aromatic herbs in a clinical setting of
URTIs. Hubbert et al. studied the eﬃcacy and tolerability of
as p r a yw i t hSalvia oﬃcinalis (containing camphor) in the
treatmentofacutepharyngitis[18].Theresearchersreported
that pain relief occurred within the ﬁrst two hours after the
ﬁrst administration. In another double-blind randomized
controlled herbal trial, Dirjomuljono et al. examined the
eﬀect of two herbs, Nigella sativa and Phyllanthus niruri,
in patients with acute tonsillopharyngitis symptoms. In
this study, the alleviation of swallowing pain and diﬃculty
was noticed only after 5-6 hours, presumably due to a
systemic eﬀect (oral tablets versus spray application in other
studies) [19]. Design of herbal studies in the URTI setting
needs to take into account the various herbal constituents
and activities in order to choose the most appropriate
route of administration. For example, Nigella sativa,aw e l l -
known herbal remedy in Islamic medicine, possesses an
antispasmodic eﬀect and can increase mucociliary clearance;
thus, a systemic rather than local activity may be expected
[20]. A third option for treating sore throat and other
URTI symptoms is with a herbal tea preparation that
may act both locally and systemically. Brinckmann et al.
demonstrated signiﬁcant relief of pain in patients with
acute pharyngitis within 5 minutes after drinking Throat
Coat, a traditional demulcent herbal tea, compared with
placebo [21]. Other promising remedies are the traditional
Japanese (Kampo medicine) formulas named Hochuekkito
(TJ-41) and Juzentaihoto (TJ-48) that stimulate the mucosal
immune system of upper respiratory tract [22]. In our study,
we designed application of aromatic oils in spray form rather
than tea or tablets. We intended to gain the local beneﬁt
of these evaporating aromatic oils, which may attain better
penetration of the tonsils’ folders and other pharyngeal
structures.
The rapid symptom improvement 20 minutes following
application of the herbal spray may be explained by an
anti-inﬂammatory and analgesic eﬀect. Indeed, human and
animal studies concluded that eucalyptus [14] and mint oil
[6] possess these eﬀects. The antitussive eﬀect of menthol
and camphor [7] and the bronchodilating eﬀect of carvacrol
[10] may also explain the rapid symptomatic relief observed
in our study. However, this study cannot conclusively
determine that the combination of the 5 herbs is indeed
essential. Further clinical studies are warranted to determine
the dosage of diﬀerent herbs in the formula for relieving
URTIsymptomsandwhethertheseherbspossesscumulative
or synergistic eﬀect.
The advantages of the aromatic preparation reported
in our study may not be limited to patients’ relief due to
symptom improvement. Plant extracts are potential sources
of antimicrobial and resistance-modifying agents and may
be used to decrease antibiotic resistance [23]. Moreover,
utilization of complementary and alternative medicine
(CAM) therapies, including herbal preparations, could
reduce prescribing antibiotics in cases when there is no
clinical indication, such as viral infections [24].
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